sodium glycididazole

Phase 3Small molecule

sodium glycididazole is one of 12 small molecule programs targeting Concurrent Chemoradiotherapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Concurrent ChemoradiotherapyTerminated

Concurrent ChemoradiotherapyPhase 3

Terminated

Competition

Competitive Landscape

11 competitors in Concurrent Chemoradiotherapy

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 2

1 2

Tuoyi

SSun Yat-sen University

Phase 2

3 3

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

2 4

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 5

INCMGA00012

Incyte

Phase 2

1 6

HLX10

Shanghai Henlius Biotech

Phase 2

1 7

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 2

1 8

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 2

1 9

S-1

Taiho Oncology, Inc.

Phase 2

1 10

Neoadjuvant Chemotherapy

JJapan Clinical Oncology Group

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Concurrent Chemoradiotherapy4 trials

A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC

Terminated·SShandong Cancer Hospital and Institute·Phase 4·NCT02721550·2 enrolled

A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC

Terminated·SShandong Cancer Hospital and Institute·Phase 4·NCT02721576·8 enrolled

A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC

Completed·SShandong Cancer Hospital and Institute·Phase 4·NCT02721563·77 enrolled

Show 1 more trial

Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Recruiting·—·Phase 2·NCT06667622·40 enrolled

Esophageal Squamous Carcinoma1 trial

A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma

Unknown status·SShandong Luye Pharmaceutical Co., Ltd.·Phase 4·NCT00642239·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for sodium glycididazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sodium glycididazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sodium glycididazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Luye Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShandong Luye Pharmaceutical Co., Ltd.

sodium glycididazole

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Concurrent Chemoradiotherapy4 trials

Esophageal Squamous Carcinoma1 trial

References

Drug Info

Quick Facts

Related News